Overall, results from the phase III Valor trial testing Lyme disease vaccine PF-07307405 “strengthen confidence” in the candidate, according to partners Pfizer Inc. and Valneva SE, with the big pharma now looking toward regulatory submissions. Investors, however, focused on the fact that the study, which demonstrated more than 70% efficacy in preventing Lyme disease in individuals, ages 5 and older, failed to hit the statistical criterion for the first prespecified analysis. Read More
In a competitive and still-needy space where Apogee Therapeutics Inc. CEO Michael Henderson noted that “even modestly differentiated products are quickly becoming blockbusters,” his firm’s IL-13 antibody zumilokibart (zumi, APG-777) has turned up satisfying phase II data in part A of the phase II atopic dermatitis (AD) experiment called Apex in moderate to severe disease. “We’re still digesting the data,” Henderson added, pointing out that the results proved better than Apogee expected at both time intervals tested. Read More
Oryon Cell Therapies, named after the Orion constellation used for navigation at night, emerged from stealth mode to announce a new round of funding and to present data from the phase Ib/IIa study of its neuron replacement therapy in patients with Parkinson’s disease at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases. Read More
T-cell engager company Kali Therapeutics Inc. licensed its lead product, CD19/BCMA/CD3 trispecific antibody KT-501, to Sanofi SA in a global deal that could be worth more than $1.2 billion. The San Mateo, Calif.-based biotech first emerged in 2024 and moved KT-501 into a phase Ia trial last week to treat adults with rheumatoid arthritis. Read More
AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026. Read More
The first day of Bio-Europe Spring, being held for the first time in Lisbon this year, featured panels on the partnering landscape in specific indications, as well as a more general panel on “Piecing Together the Therapeutic Landscape with Analyst Insights.” One theme of the panel was that by and large, large companies are looking for deals with companies that fit with their existing programs – but that such a fit can come in many forms. Read More
Laigo Bio BV has extended its seed round to €17 million (US$19.8 million), after making progress with translating its novel E3 ubiquitin ligase targeted protein degradation technology toward the clinic. Read More
With incidence of kidney cancer rising in the U.K., the National Institute for Health and Care Excellence (NICE) published its first comprehensive guidelines for diagnosing and treating the disease. Read More
Crushing the hopes of drug and device companies, the U.S. Supreme Court’s March 23 orders list showed it denied cert in Takeda Pharmaceutical v. Painters & Allied Trades, which sought to rein in the expansion of class action lawsuits. Read More
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the abnormal accumulation of α-synuclein, a protein that forms toxic aggregates and spreads between cells, damaging them. At the 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), held from March 17 to 21, 2026, in Copenhagen, several strategies were presented that aim to modify the course of the disease and offer real alternatives to purely symptomatic treatments. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Azitra, Bioxytran, Blue Water Acquisition, Bonus, Capsovision, Earendil, Hansa, Verily. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Biodesix, Immunobrain, Innovative Medical, Koite, Pharvaris, Qiagen. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Caris, Co-Diagnostics, Cosara, Ferring, Hamamatsu, Ibex, Sakura. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Eledon, Intrabio, Novo Nordisk, Rhythm, Siemens. Read More
